Solana

Solana Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Solana (HSDT) as of Oct 21, 2026 is 0.10. In the previous year, Net Debt to Free Cash Flow Ratio was 0.49 — a change of -80.15% (lower).

Net Debt/FCF

0.10

YoY

-80.15%

Last updated:

Net Debt to Free Cash Flow Ratio of Solana is 2024 0.10 . Net Debt to Free Cash Flow Ratio of Solana was 2023 0.49 . It decreases by -80.15% lower compared to the previous year.

The Solana Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2017
0.23 USD
Jan 1, 2018
0.59 USD
Jan 1, 2019
0.23 USD
Jan 1, 2020
0.27 USD
Jan 1, 2021
0.82 USD
Jan 1, 2022
1.01 USD
Jan 1, 2023
0.49 USD
Jan 1, 2024
0.10 USD
The Solana Net Debt/FCF history
YEARNet Debt/FCFYoY
0.10-80.15%
0.49-51.31%
1.01+23.13%
0.82+198.11%
0.27+21.15%
0.23-61.52%
0.59+152.42%
0.23-302.38%
-0.12-202.04%
0.11-282.05%
-0.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Solana Stock analysis

What does Solana do? Helius Medical Technologies develops and markets the PoNS device, a portable neuromodulation stimulator for neurological wellness. The company focuses on non-invasive platform technologies that enhance the brain's healing ability. The PoNS device is authorized as a class II medical device in Canada for short-term treatment of chronic balance deficits caused by mild-to-moderate traumatic brain injury, used alongside physical therapy. It delivers non-invasive neurostimulation to the tongue to induce neuromodulation. Helius Medical Technologies targets healthcare providers and rehabilitation centers that treat patients with traumatic brain injury. The company's product is designed for use in clinical settings under professional guidance, specifically for patients requiring short-term balance deficit therapy. The PoNS device is positioned as a complementary treatment within physical therapy protocols for neurological rehabilitation. The firm's revenue model is based on the sale of the PoNS device to healthcare institutions and rehabilitation facilities. These institutions purchase the device for use in their treatment programs, leveraging its non-invasive neurostimulation technology to address balance deficits in patients with mild-to-moderate traumatic brain injury. The company's focus on neurological wellness through non-invasive solutions drives its commercial strategy. Solana is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Solana stock

Net Debt to Free Cash Flow Ratio of Solana is 0.10 in 2024.

Net Debt to Free Cash Flow Ratio of Solana changed from 0.49 to 0.10, representing a -80.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Solana since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Solana with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Solana

All Key Metrics — Solana